Novel aspects of oxidative stress-associated carcinogenesis

Antioxidants and Redox Signaling

Volumn 8, Issue 7-8, 2006, Pages 1373-1377

  Toyokuni, Shinya ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

NITROGEN; REACTIVE OXYGEN METABOLITE;

CARCINOGENESIS; GENE LOCUS; MUTATION; OXIDATION; OXIDATIVE STRESS; PRECANCER; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION;

ANIMALS; CARCINOGENS; FREE RADICALS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HUMANS; MODELS, BIOLOGICAL; MUTATION; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; OXIDATIVE STRESS; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES;

EID: 33746898269     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2006.8.1373     Document Type: Short Survey

References (52)

1. Ahsan M, Masutani H, Yamaguchi Y, Kim Y, Nosaka K, Matsuoka M, Nishinaka Y, Maeda M, and Yodoi J. Loss of interleukin-2-dependency in HTLV-I-infected T cells on gene silencing of thioredoxin-binding protein-2. Oncogene 25: 2181-2189, 2006.
2. Baselga J, Norton L, Albanell J, Kim Y, and Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58: 2825-2831, 1998.
3. Bodnar J, Chatterjee A, Castellani L, Ross D, Ohmen J, Cavalcoli J, Wu C, Dains K, Catanese J, Chu M, Sheth S, Charugundla K, Demant P, West D, de Jong P, and Lusis A. Positional cloning of the combined hyperlipidemia gene Hyplip1. Nat Genet 30: 110-116, 2002.
4. Capdeville R, Buchdunger E, Zimmermann J, and Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1: 493-502, 2002.
5. ink4. Mol Cell Biol 15: 2682-2688, 1995.
6. Dizdaroglu M. Chemical determination of free radical-induced damage to DNA. Free Radic Biol Med 10: 225-242, 1991.
7. Dutta KK, NIshinaka Y, Masutani H, Akatsuka S, Aung TT, Shirase T, Lee W-H, Hiai H, Yodoi J, and Toyokuni S. Thioredoxin-binding protein-2 is a target gene in oxidative stress-induced renal carcinogenesis. Lab Invest 85: 798-807, 2005.
8. Ekbom A, Helmick C, Zack M, and Adami H. Ulcerative colitis and colorectal cancer: A population-based study. N Engl J Med 323: 1228-1233, 1990.
9. Forman D, Newell D, Fullerton F, Yarnell J, Stacey A, Wald N, and Sitas F. Association between infection with Helicobacter pylori and risk of gastric cancer: Evidence from a prospective investigation. BMJ 302: 1302-1305, 1991.
10. Futreal P, Coin L, Marshall M, Down T, Hubbard T, Wooster R, Rahman N, and Stratton M. A census of human cancer genes. Nat Rev Cancer 4: 177-183, 2004.
11. Goldberg S, Miele M, Hatta N, Takata M, Paquette-Straub C, Freedman L, and Welch D. Melanoma metastasis suppression by chromosome 6: Evidence for a pathway regulated by CRSP3 and TXNIP. Cancer Res 63: 432-440, 2003.
12. Grodstein F, Speizer F, and Hunter D. A prospective study of incident squamous cell carcinoma of the skin in the nurses' health study. J Natl Cancer Inst 87: 1061-1066, 1995.
13. Halliwell B and Gutteridge JMC. Free radicals in biology and medicine. Oxford: Clarendon Press, 1999, p 58.
14. 3 inhibits tumor cell growth by blocking cell-cycle progression. Oncogene 22: 4035-4046, 2003.
15. Hirai F, Motoori S, Kakinuma S, Tomita K, Indo H, Kato H, Yamaguchi T, Yen H, St. Clair D, Nagano T, Ozawa T, Saisho H, and Majima H. Mitochondrial signal lacking manganese superoxide dismutase failed to prevent cell death by reoxygenation following hypoxia in a human pancreatic cancer cell line, KP4. Antioxid Redox Signal 6: 523-535, 2004.
16. INK4A tumor suppressor gene after weeks of iron-mediated oxidative damage during rat renal carcinogenesis. Am J Pathol 160: 419-424, 2002.
17. Hodgson J and Darnton A. The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure. Ann Occup Hyg 44: 565-601, 2000.
18. Hui T, Sheth S, Diffley J, Potter D, Lusis A, Attie A, and Davis R. Mice lacking thioredoxin interacting protein provide evidence linking cellular redox state to appropriate response to nutritional signals. J Biol Chem 279: 24387-24393, 2004.
19. 3 up-regulated protein 1 (VDUP1) expression in gastrointestinal cancer and its relation to stage of disease. Anticancer Res 22: 4045-4048, 2002.
20. Iuchi K, Aozasa K, Yamamoto S, Mori T, Tajima K, Minato K, Mukai K, Komatsu H, Tagaki T, and Kobashi Y. Non-Hodgkin's lymphoma of the pleural cavity developing from long-standing pyothorax: summary of clinical and pathological findings in thirty-seven cases. Jpn J Clin Oncol 19: 249-257, 1989.
21. Joensuu H. Treatment of inoperable gastrointestinal stromal tumor (GIST) with imatinib (Glivec, Gleevec). Med Klin (Munich) 97(suppl 1): 28-30, 2002.
22. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, and Sherr CJ. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci U S A 95: 8292-8297, 1998.
23. Kim A, Zhong W, and Oberley T. Reversible modulation of cell cycle kinetics in NIH/3T3 mouse fibroblasts by inducible overexpression of mitochondrial manganese superoxide dismutase. Antioxid Redox Signal 6: 489-500, 2004.
24. Kitano H. Cancer as a robust system: Implications for anticancer therapy. Nat Rev Cancer 4: 227-235, 2004.
25. Loeb LA. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 51: 3075-3079, 1991.
26. Nishigori C, Hattori Y, and Toyokuni S. Role of reactive oxygen species in skin carcinogenesis. Antioxid Redox Signal 6: 561-570, 2004.
27. 3 up-regulated protein 1 in human T-cell leukemia virus type I-dependent T-cell transformation: Implications for adult T-cell leukemia leukemogenesis. Cancer Res 64: 1287-1292, 2004.
28. 3 up-regulated protein 1 as a negative regulator of thioredoxin function and expression. J Biol Chem 274: 21645-21650, 1999.
29. Nishiyama Y, Suwa H, Okamoto K, Fukumoto M, Hiai H, and Toyokuni S. Low incidence of point mutations in H-, K- and N-ras oncogenes and p53 tumor suppressor gene in renal cell carcinoma and peritoneal mesothelioma of Wistar rats induced by ferric nitrilotriacetate. Jpn J Cancer Res 86: 1150-1158, 1995.
30. Oberley L. Anticancer therapy by overexpression of superoxide dismutase. Antioxid Redox Signal 3: 461-472, 2001.
31. Oberley T. Mitochondria, manganese superoxide dismutase, and cancer. Antiox Redox Signal 6: 483-487, 2004.
32. Oberley T, Xue Y, Zhao Y, Kiningham K, Szweda L, and St. Clair D. In situ reduction of oxidative damage, increased cell turnover, and delay of mitochondrial injury by overexpression of manganese superoxide dismutase in a multistage skin carcinogenesis model, Antioxid Redox Signal 6: 537-548, 2004.
33. Ohshima H, Tatemichi M, and Sawa T. Chemical basis of inflammation-induced carcinogenesis. Arch Biochem Biophys 417: 3-11, 2003.
34. Oikawa S and Kawanishi S. Site-specific DNA damage at GGG sequence by oxidative stress may accelerate telomere shortening. FEBS Lett 453: 365-368, 1999.
35. Oka S, Liu W, Masutani H, Hirata H, Shinkai Y, Yamada S, Yoshida T, Nakamura H, and Yodoi J. Impaired fatty acid utilization in thioredoxin binding protein-2 (TBP-2)-deficient mice: A unique animal model of Reye syndrome. FASEB J 20: 121-123, 2006.
36. Pani G, Colavitti R, Bedogni B, Fusco S, Ferraro D, Borrello S, and Galeotti T. Mitochondrial superoxide dismutase: A promising target for new anticancer therapies. Curr Med Chem 11: 1299-1308, 2004.
37. Park S, Kim W, Choi U, Han S, Kim Y, Kim Y, Chung M, Nam K, Kim D, Cho S, and Hahm K. Amelioration of oxidative stress with ensuing inflammation contributes to chemoprevention of H. pylori-associated gastric carcinogenesis. Antioxid Redox Signal 6: 549-560, 2004.
38. Preston D, Kusumi S, Tomonaga M, Izumi S, Ron E, Kuramoto A, Kamada N, Dohy H, Matsuo T, and T M. Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987. Radiat Res 137: S68-S97, 1994.
39. Ridnour L, Oberley T, and Oberley L. Tumor suppressive effects of MnSOD overexpression may involve imbalance in peroxide generation versus peroxide removal. Antioxid Redox Signal 6: 501-512, 2004.
40. Sen C and Packer L. Antioxidant and redox regulation of gene transcription. FASEB J 10: 709-720, 1996.
41. Siddiqui I, Afaq F, Adhami V, Ahmad N, and Mukhtar H. Antioxidants of the beverage tea in promotion of human health. Antioxid Redox Signal 6: 571-582, 2004.
42. Slamon D, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, and Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001.
43. Steenken S. Purine bases, nucleosides, and nucleotides: Aqueous solution redox chemistry and transformation reactions of their radical reactions and e· and ·OH adducts. Chem Rev 89: 503-520, 1989.
44. Steinmetz K and Potter J. Vegetables, fruit, and cancer prevention: A review. J Am Diet Assoc 96: 1027-1039, 1996.
45. Sugimura T. Multistep carcinogenesis: a 1992 perspective. Science 258: 603-607, 1992.
46. INK4A tumor suppressor genes in oxystress-induced renal cell carcinoma of rats. Oncogene 18: 3793-3797, 1999.
47. Toyokuni S. Reactive oxygen species-induced molecular damage and its application in pathology. Pathol Int 49: 91-102, 1999.
48. Toyokuni S, Akatsuka S, Aung TT, and Dutta KK. Free radical-induced carcinogenesis: target genes and fragile genome sites. Free Radic Res 39 (suppl 1): S30, 2005.
49. Uchida K. 4-Hydroxy-2-nonenal: A product and mediator of oxidative stress. Prog Lipid Res 42: 318-343, 2003.
50. Vogelstein B and Kinzler KW. The genetic basis of human cancer. New York: McGraw-Hill, 1998.
51. von Zglinicki T, Pilger R, and Sitte N. Accumulation of single-strand breaks is the major cause of telomere shortening in human fibroblasts. Free Radic Biol Med 28: 64-74, 2000.
52. Zhong W, Yan T, Webber M, and Oberley T. Alteration of cellular phenotype and responses to oxidative stress by manganese superoxide dismutase and a superoxide dismutase mimic in RWPE-2 human prostate adenocarcinoma cells. Antioxid Redox Signal 6: 513-522, 2004.